References
Barcellini W, Fattizzo B, Zaninoni A (2018) Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol 10:857–872. https://doi.org/10.1080/1744666x.2018.1521722
Dierickx D, Kentos A, Delannoy A (2015) The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood 21:3223–3229. https://doi.org/10.1182/blood-2015-01-588392
Reynaud Q, Durieu I, Dutertre M et al (2015) Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev 4:304–313. https://doi.org/10.1016/j.autrev.2014.11.014
Mohty M, Brissot E, Savani BN et al (2013) Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant 10:1416–1420. https://doi.org/10.1016/j.bbmt.2013.05.011
Ratnasingam S, Walker PA, Tran H et al (2016) Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv 1:31–35. https://doi.org/10.1182/bloodadvances.2016001412
Jager U, Barcellini W, Broome CM et al (2019) Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev 100648. https://doi.org/10.1016/j.blre.2019.100648
Miao C, Junling Z (2017) A systematic review of low-dose rituximab in the treatment of warm autoimmune hemolytic anemia. Basic Clin Med 37(10):1444–1448
Muhsen IN, Alahmari A, Alnahedh M et al (2019) Bortezomib for immune thrombocytopenia and autoimmune hemolytic anemia. Hematol Oncol Stem Cell Ther. https://doi.org/10.1016/j.hemonc.2019.05.006
Funding
The work was supported by the National Natural Science Foundation of China (NSFC) (81970106) and the Beijing Natural Science Foundation (7192168).
Author information
Authors and Affiliations
Contributions
D.B.Z., B.H. and M.C. designed research. M. C, J.L.Z., J.L., C. Y, L. Z, W.W., H.C.C. and Y.F.Y. performed research. M.C. analyzed data and wrote the paper. B.H. revised the final draft. All authors reviewed and edited the final manuscript before submission.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of ethics
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Peking Union Medical College Hospital and with the 1964 Helsinki declaration and its later amendments.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chen, M., Zhuang, J., Yang, C. et al. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia. Ann Hematol 99, 1141–1143 (2020). https://doi.org/10.1007/s00277-020-03976-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-03976-w